Orchid Pharma Limited
NSE: ORCHPHARMA · Pharmaceuticals
Snapshot
Unlock Orchid Pharma Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Orchid Pharma Limited is a pharmaceutical company based in Chennai that specialises in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs), bulk actives, and finished dosage formulations. The company maintains a multi-therapeutic presence across segments including anti-infectives, cardiovascular, and nutraceuticals, while also providing pharmaceutical research and development services.
Business Model
The company generates revenue through the sale of a diverse pharmaceutical portfolio, including oral and injectable cephalosporins, veterinary products, and non-antibiotics. It further monetises its expertise by offering regulatory support, pharmacovigilance, and contract research services to international clients across approximately 40 countries.
- Incorporation Year:1992
- Export Reach:40 countries
Growth Outlook
Growth is expected to be driven by the company's focus on new drug discovery systems and the expansion of its research and development capabilities. Continued penetration into international markets and the leveraging of its diverse therapeutic portfolio remain key strategic priorities.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international regulatory standards and potential audits of its manufacturing facilities.
- Market Competition. Intense competition in the generic pharmaceutical and API sectors may exert pressure on profit margins and market share.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials and active pharmaceutical ingredients could impact production costs.
- Currency Risk. As an exporter to approximately 40 countries, the company is exposed to foreign exchange rate volatility affecting its international revenue streams.
Start your research today
Unlock AI insights, financials, peers and live data on Orchid Pharma Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹943 Cr
TTM · consolidated
NET PROFIT
₹9 Cr
TTM · consolidated
EPS
₹1.61
TTM · consolidated
RETURN ON EQUITY
0.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
1.5%
TTM · consolidated
P/E
593.0x
Q1 FY27 · consolidated
EV/EBITDA
78.1x
Q1 FY27 · consolidated
EBITDA MARGIN
7.1%
TTM · consolidated
NET PROFIT MARGIN
1.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Orchid Pharma LimitedORCHPHARMA | ₹4,842 Cr | 592.95 | 78.06 | 10.8% | 7.1% | 0.7% | 1.5% | +32.3% |
FDC LimitedFDC | ₹5,581 Cr | 19.07 | 11.66 | 3.4% | 21.7% | 12.3% | 16.1% | -25.5% |
RPG Life Sciences LimitedRPGLIFE | ₹4,501 Cr | 37.68 | 24.51 | 11.8% | 24.5% | 21.0% | 27.6% | +14.7% |
Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,482 Cr | 155.81 | 54.77 | 17.5% | 48.8% | 18.2% | 19.8% | +7.9% |
Gufic Biosciences LimitedGUFICBIO | ₹4,462 Cr | 60.78 | 28.68 | 16.7% | 17.0% | 11.6% | 16.9% | +22.1% |
Novartis IndiaNOVARTIND | ₹4,066 Cr | 43.62 | 30.20 | -0.5% | 37.5% | 11.7% | 16.1% | +76.7% |
As of Q1 FY27
Financials
Orchid Pharma Limited
NSE: ORCHPHARMA · Pharmaceuticals
Snapshot
Unlock Orchid Pharma Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Orchid Pharma Limited is a pharmaceutical company based in Chennai that specialises in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs), bulk actives, and finished dosage formulations. The company maintains a multi-therapeutic presence across segments including anti-infectives, cardiovascular, and nutraceuticals, while also providing pharmaceutical research and development services.
Business Model
The company generates revenue through the sale of a diverse pharmaceutical portfolio, including oral and injectable cephalosporins, veterinary products, and non-antibiotics. It further monetises its expertise by offering regulatory support, pharmacovigilance, and contract research services to international clients across approximately 40 countries.
- Incorporation Year:1992
- Export Reach:40 countries
Growth Outlook
Growth is expected to be driven by the company's focus on new drug discovery systems and the expansion of its research and development capabilities. Continued penetration into international markets and the leveraging of its diverse therapeutic portfolio remain key strategic priorities.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international regulatory standards and potential audits of its manufacturing facilities.
- Market Competition. Intense competition in the generic pharmaceutical and API sectors may exert pressure on profit margins and market share.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials and active pharmaceutical ingredients could impact production costs.
- Currency Risk. As an exporter to approximately 40 countries, the company is exposed to foreign exchange rate volatility affecting its international revenue streams.
Start your research today
Unlock AI insights, financials, peers and live data on Orchid Pharma Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹943 Cr
TTM · consolidated
NET PROFIT
₹9 Cr
TTM · consolidated
EPS
₹1.61
TTM · consolidated
RETURN ON EQUITY
0.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
1.5%
TTM · consolidated
P/E
593.0x
Q1 FY27 · consolidated
EV/EBITDA
78.1x
Q1 FY27 · consolidated
EBITDA MARGIN
7.1%
TTM · consolidated
NET PROFIT MARGIN
1.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27